Caplacizumab (Cablivi)

Mechanism of action

A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).

Diseases for which it is used

• Thrombotic thrombocytopenic purpura

History of changes in FDA indication

• 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

History of changes in EMA indication

• 8/30/2018: Initial authorization

Patient Drug Information

• Caplacizumab (Cablivi) Package Insert

Also known as

• Code name: ALX-0081
• Generic name: caplacizumab-yhdp
• Brand name: Cablivi